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The targeting of nutraceutical treatment to skeletal muscle damage is an emerging area of research, driven by the need
for new therapies for a range of muscle-associated diseases. L-Carnitine (CARN) is an essential nutrient and plays a key
role in mitochondrial 𝛽-oxidation and in the ubiquitin-proteasome system regulation. As a dietary supplement to improve
athletic performance, CARN has been studied for its potential to enhance 𝛽-oxidation. However, CARN effects on myogenesis,
mitochondrial activity, and hypertrophy process are not completely elucidated. This in vitro study aims to investigate CARN
role on skeletal muscle remodeling, differentiation process, and myotubes formation. We analyzed muscle differentiation and
morphological features in C2C12 myoblasts exposed to 5mM CARN. Our results showed that CARN was able to accelerate C2C12
myotubes formation and induce morphological changes, characterizing the start of hypertrophy process. In addition, CARN
improved AKT activation and downstream cellular signaling pathways involved in skeletal muscle atrophy process prevention.
Also, CARN positively regulated the pathways involved in oxidative stress defense. In this work, we provide an interesting
novel mechanism of the potential therapeutic use of CARN to treat pathological conditions characterized by skeletal muscle
morphological and functional impairment, oxidative stress production, and atrophy process in aging.
1. Introduction
The role of many nutrients in maintaining good health and
prolonging human lifespan has been clearly demonstrated
over the past three decades. In particular, plant food stuffs,
animal foods, and lipids have been shown to have protective
effects against several chronic pathologies such as age-related
diseases, including cardiovascular [1], neurodegenerative [2],
and inflammatory diseases [3], diabetes [4], and myopathies
[5]. In these pathologies, the skeletal muscle is the critical
target.
The deterioration of skeletal muscle structure and func-
tion leads to clinically relevant complaints, including progres-
sive strength loss, fatigue, myalgia, and cramps. Important
progress has been made in the comprehension of the molec-
ular mechanisms underlying muscle myopathies. However,
the treatment of muscle diseases is mainly symptom-oriented
and includes physical therapy and exercise, but no specific
pharmacologic interventions are currently available [5, 6].
Considering the lack of therapies for sarcopenia and
muscle atrophy, the idea that nutritional supplements might
have beneficial effects in muscle damages treatment is expe-
riencing renewed interest. Conclusions about how beneficial
nutritional supplements are for myopathy treatment are
complicated by a lack of unequivocal results and flaws in the
choice of supplements. Based on the physiological roles in
muscle biochemistry and bioenergetics, it is not surprising
that carnitine role has been studied intensively.
Carnitine (CARN) is a derivative amino acid playing
an essential role in cellular energy metabolism due to the
acylation of its 𝛽-hydroxyl group and in the long-chain fatty
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acids transport into themitochondrial matrix [7], where they
undergo 𝛽-oxidation.
CARN can be supplied with diet, especially with foods
of animal origin. The skeletal muscle is the most relevant
depository of CARN (95% of the total body stores), and its
availability is critical for the physiological bioenergetics of
this tissue. CARN deficiency greatly affects skeletal muscle
function as found in the presence of primary and secondary
deficiencies [8].
In accordance with CARN role in skeletal muscle, a large
amount of research was directed towards investigating the
effects of CARN supplementation on exercise performance
[9], particularly in ameliorating and accelerating recovery
from exercise-induced muscle injury [7]. It has been found
that supplemental CARN is effective in attenuating signs of
tissue damage induced by lengthening or intense contractions
also in sarcopenic muscle [10]. In particular, evidence from
both animal and clinical studies demonstrated that CARN
treatment positively influences many different mechanisms
involved in pathologic skeletal muscle loss [11].
The observed benefits of CARN in preventing load-
induced muscle injury have been attributed to its role as
antioxidant [12]. In skeletal muscle, reactive oxygen species
(ROS) and nitrogen species are physiologically synthesized
at low levels and are required for normal force produc-
tion. When ROS production overtakes tissue antioxidant
capacity, oxidative stress activates pathophysiologic signaling
leading to proteolysis and apoptosis within the myofibers
[13]. This sequence of events is considered a major cause
of sarcolemmal damage and the origin of reduced muscle
strength capacity that contributes to fatigue [14].
However, the effects of CARN on myogenesis, myotubes
formation, muscle atrophy, andmuscle regeneration have not
yet been completely elucidated.
Aimof this study is to clarifyCARNeffects onmyogenesis
in order to speculate a novel nutraceutical approach in the
treatment of muscle injury and muscle atrophy process.
2. Materials and Methods
2.1. Materials. Mouse C2C12 myoblastic cells were pur-
chased from the European Collection of Animal Cell
Cultures (ECACC). Reagents were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Primary antibodies
against AKT (C-20), calnexin (H-70), CAMKII (M-176),
ERK1 (K-23), ERK2 (C-14), GAPDH (FL-335), IGF-1 recep-
tor 𝛽 (C-20), Myf5 (c-20), MyHC (H-300), MyoD (C-
20), myogenin (D-10), pERK1/2 (E-4), anti-p53 (FL-393),
p70S6 (C-18), pp70S6 (sc-7984), SOD2 (FL-222), peroxidase-
conjugated secondary antibodies for Western blot analysis
and rhodamine-conjugated antibodies for Immunofluores-
cence analysis were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Primary antibodies phospho-
AKT (Ser473) (D9E) XP and phospho-AMPK alpha (Thr172)
(40H9) were purchased from Cell Signaling Technology
(Danvers, MA, USA). Antibody against Phalloidin (Alexa
Fluor 488 Phalloidin, molecular probes-Invitrogen) was pur-
chased by Life Technologies (Carlsbad, California, USA).
2.2. Cell Culture. C2C12 cells were maintained at 37∘C in
humidified 5% CO
2
atmosphere in a growth medium (GM)
containing DMEM (Dulbecco Modified Eagle Medium)
supplemented with 20% (v/v) FBS (Fetal Bovine Serum),
1% penicillin streptomycin, and 1% L-glutamine up to 70%
confluence. Cell differentiation was initiated by placing 70%
confluent cell cultures in differentiation medium (DM),
containing DMEM supplemented with 1%HS (horse serum),
antibiotics, and 1% L-glutamine. In our in vitro differentiation
model, early myotubes appeared 24–48 hours (h) after serum
starvation and neomyotubes formation was completed after
72 h [15].
2.3. Experimental Procedures. Proliferating cells, differenti-
ating myocytes, and neomyotubes were treated with 5mM
CARN, the bioactive L-isomer of carnitine. This dose was
chosen after a preliminary dose-response assay to establish
the effective dose for the treatment (data not shown). In
the control cells CARN was not added to medium. Figure 1
explains experimental study design in each phase of the
protocol, with cell confluence percentage and treatments start
time and duration.
2.4. Growth Curve and Cell Viability Test. To study CARN
role in C2C12 myoblast proliferation, we performed growth
curve assay as described in [16]. Briefly, C2C12 myoblasts
were plated in 60mm × 15mm culture dishes at 40%
confluence and grown in GM with or without CARN and
in DM. Medium was changed every 24 h and the experiment
lasted until control cells achieved 70% of confluence (3 days).
Every day, the cells were trypsinized, stained with trypan
blue, and counted using a hemocytometer.The average values
for each single day were used to plot a growth curve.
Cell viability was calculated by dividing the nonstained
viable cell count by the total cell count. In addition, mor-
phological changes were examined daily by phase contrast
microscopy.
2.5. Western Blot Analysis. Protein extracts, performed as
described elsewhere [17], were obtained from cell cultures by
using the following lysis buffer containing: 50mM Tris/HCl,
pH 7.4, 150mM NaCl, 1% Triton X-100, 1mM sodium ortho-
vanadate (Na
3
VO
4
), 1mM EDTA, 1mM PMSF, 1mg/mL
aprotinin, 1mg/mL leupeptin, and 1mg/mL pepstatin.
Aliquots of 30 𝜇g supernatant proteins, quantified using
Bradford method, were resolved on SDS-PAGE gel and
transferred onto nitrocellulose membrane (Protran, What-
man Schleicher & Schuell). The membranes were incubated
with specific primary antibodies and then with HRP conju-
gated anti-species-specific secondary antibodies. To confirm
equal protein loading per sample, antibody anti-calnexin
or anti-GAPDH was used. Quantitative measurement of
immunoreactive bands intensities, visualized by an enhanced
chemiluminescencemethod (Amersham Pharmacia Biotech,
Piscataway, NJ, USA), was performed by densitometric anal-
ysis using the Scion Image software (Scion Corporation,
Frederick, MD, USA). Data were then converted into fold-
changes (FC) of the controls [18].
Oxidative Medicine and Cellular Longevity 3
Mature 
myotubes 
(MyHC+)
MyoD/Myf5 Myog/Myf6
Myoblasts
Early myotubes 
(MyHC+)
(a)
Proliferative phase
GM
GM + CARN
DM
DM
DM + CARN
confluence confluence
DM
DM + CARN
myotube
Differentiation phase Post-differentiation phase
L-Carnitine 5mM
24h
48h
72h
24h
24h
48h
72h
T0 = neo
formed
T0 = 70%T0 = 40%
(b)
Figure 1: Experimental protocol. C2C12 cells in proliferative phase, in differentiation, and in postdifferentiation were treated with 5mM
CARN.
2.6. Immunofluorescence Analysis. C2C12 cells, fixed and
permeabilized as described in [19], were blocked with PBS
containing 1% bovine serum albumin. Slides or cells were
then immunostained with specific antibodies rhodamine-
conjugated and nuclei-revealed with DAPI staining. Slides
were mounted withMoviol. Cells were observed using Nikon
Eclipse 50I microscopy and images were captured using
Nis-Elements D 4.00 software (Nikon Instruments Europe
BV, Netherlands). Data were displayed and analyzed using
Adobe Photoshop CS4. Live C2C12 cells were examined and
images acquired by phase contrastmicroscopy using the same
microscope and digital system described above.
2.7. Statistical Analysis. All experiments were performed
three times. Data are presented as the mean ± SD. Statistical
significances were assessed by 𝑡-test or Anova tests as appro-
priate. Results were considered significant when 𝑃 ≤ 0.05.
3. Results
3.1. CARN Action during Myoblast Proliferation and Myocytes
Commitment. We initially sought to determine the effect
of exogenous CARN supplementation on myoblasts cell
proliferation (Figure 2). Cells were cultured in three different
media for three days: GM, GM supplemented with 5mM
CARN, and DM. CARN action on C2C12 proliferation
capacity was studied assessing viability test and growth curve
trend. DM exerted an inhibitory effect on C2C12 proliferative
capacity, differently from CARN and GM superimposable
effect (Figure 2(b)). Under the conditions investigated, cell
viability was not negatively affected by the CARN treatment
(Figure 2(a)). This result was confirmed by unstimulated
p53 expression after 3 days of CARN supplementation
(Figure 2(b)).
Also, while GM and CARN treated cells preserved
their morphological characteristics at confluence, DM cells
showed a morphology more similar to polarized cells
(Figure 2(c)).
Because myogenic differentiation proceeds through irre-
versible cell cycle arrest of myoblasts [20], these data suggest
that CARN is not still able at this stage to support the first step
of differentiation process.
Skeletal muscle differentiation is governed by tight reg-
ulation of both activity and expression of a number of
transcription factors, particularly the MRFs family members
(MyoD, Myf5, Myogenin, and Myf6) [21]. Among these,
MyoD and Myf5 are closely related to commitment process
and early myogenic differentiation. Treatment of C2C12
myoblasts with CARN significantly increased MyoD protein
level similarly to DM (FC: CARN 1.43 ± 0.04, FC: DM 1.51 ±
0.06;𝑃 ≤ 0.02 versusGM
𝑡=0
,𝑃 ≤ 0.05 versusGM24 h;GM
𝑡=0
versus GM, CARN, DM ∙𝑃 ≤ 0.001 Anova test, Figure 2(b)).
As a complementary approach, we analyzed the mor-
phology of CARN myoblasts by Immunofluorescence anal-
ysis performed using antibody against Myf5 and MyoD.
Remarkably, CARN andDMmyoblasts Immunofluorescence
data were superimposable (Figures 3(a) and 3(b)). CARN
stimulation caused important cell morphology changes in
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Figure 2: CARN action during C2C12 proliferation phase. (a) Growth curve: CARN did not significant modify C2C12 proliferative potential
and did not induce cytotoxic effects. (b) CARN treatment does not modify p53 protein levels while it increases MyoD protein content after
3 days of treatment. (c) Phase contrast images reveal the morphological features of the cells in proliferation. Representative immunoblots of
analyzed proteins are shown. Scale bar 200𝜇m. Significance: (a) ∗𝑃 ≤ 0.05 DM versus GM and (b) p53 ∗𝑃 ≤ 0.05 DM versus GM𝑡=0. MyoD:
∙
𝑃 ≤ 0.001 Anova test, ∗𝑃 ≤ 0.05 GM versus GM𝑡=0, CARN versus GM𝑡=0, DM versus GM𝑡=0,
∘
𝑃 ≤ 0.05 CARN versus GM, and DM versus
GM.
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respect to GM. In particular, at 48 h, myoblasts lost the
circular shape characterizing the GM cells to achieve an
elongatedmorphology.This observation is further confirmed
by Phalloidin Immunofluorescence assay (Figure 3(c)).
Together, these results suggest that CARN, although it
does not arrest cell cycle, could enhanceMRFs expression and
then promote myoblasts commitment during proliferative
phase.
3.2. CARN Action during Myoblast Differentiation: Enhancing
Myotubes Formation. We investigated CARN action during
the different phases of muscle differentiation. To induce
differentiation, C2C12 myoblasts were maintained in GM up
to ∼70% confluence (time 0) and then shifted in DM or DM
supplemented with 5mMCARN. Differentiating C2C12 cells
were observed after 24, 48, and 72 hours (Figure 1). To analyze
the possible effect of CARN on myogenesis progression,
the protein levels of muscle-specific markers myogenin and
MyHC were determined by Western blot analysis. As shown
in Figure 4(a), myogenin and MyHC amount were increased
byCARNpresence (DMversusCARN ∙𝑃 ≤ 0.001Anova test,
in particular FCmyogenin 48 h: DM 0.64±0.02, CARN 1.47±
0.08, 𝑃 ≤ 0.02; myogenin 72 h: DM 0.41 ± 0.03, CARN 0.87 ±
0.02, 𝑃 ≤ 0.02; FCMyHC 24 h: DM 2.60±0.34, CARN 4.37±
0.75,𝑃 ≤ 0.05;MyHC48 h:DM 3.25±0.81, CARN 7.95±0.02,
𝑃 ≤ 0.01; MyHC 72 h: DM 7.31 ± 0.07, CARN 9.30 ± 0.28,
𝑃 ≤ 0.005), indicating that CARN could promote myotubes
formation. Moreover, we investigated whether CARN was
able to modify morphological features of C2C12 cells after
24 h of differentiation, when myoblasts start to fuse in new
myotubes. Immunofluorescence assay indicated that there
is a higher myotubes number in CARN stimulated C2C12
group compared to control, confirming that CARN is able
to enhance myotubes formation (Figure 4(b)). At the end of
differentiation process, brightfield microscopy revealed that
CARN myotubes exhibited increased diameter and length
compared to control cells (Figure 4(c)).
3.3. CARN Action during Myoblast Differentiation: Signaling
Pathway Activation. We investigated whether CARN was
involved in skeletal differentiation, analyzing the main sig-
naling pathways involved in the process: IGF-1/AKT/p70S6
and extracellular signal-regulated kinase 1/2 (ERKs). Skeletal
muscle is a tissue highly responsive to IGF-1/AKT/p70S6.
IGF-1 has been shown to be able to induce hypertrophy
through either autocrine or paracrine mechanisms [22, 23].
AKT action has been linked to skeletal muscle development,
regeneration, and hypertrophy through several pathways that
culminate in stimulation of protein synthesis, inhibition of
atrophy, and prevention of cell death [24]. p70S6K, a positive
regulator of protein translation, is an AKT target [25]. ERKs
can be activated by a variety of growth factors/mitogens.
ERKs activation has been shown to be crucial for growth
factor-induced myoblasts proliferation, fusion, and hence
myoblasts differentiation [26]. As shown in Figure 5(a),
CARN significantly increased the amount of IGF-1 receptor
(DM versus CARN ∙𝑃 ≤ 0.001 Anova test, in particular 24 h:
DM 0.91±0.03, CARN 1.16±0.06,𝑃 ≤ 0.02; 48 h:DM 1±0.04,
CARN 1.26 ± 0.02, 𝑃 ≤ 0.01; 72 h: DM 0.95 ± 0.01, CARN
1.31±0.03,𝑃 ≤ 0.002) and promotedAKT (∙𝑃 ≤ 0.001Anova
test, in particular 24 h: DM 1.28 ± 0.06, CARN 2.09 ± 0.23,
𝑃 ≤ 0.02; 48 h: DM 2.01 ± 0.07, CARN 3.08 ± 0.28, 𝑃 ≤ 0.02;
72 h: DM 2.57 ± 0.39, CARN 4.28 ± 0.75, 𝑃 ≤ 0.05) and
p70S6 kinase phosphorylation (24 h: DM 2.37 ± 0.61, CARN
3.55±0.28, 𝑃 ≤ 0.05; 48 h: DM 3.79±0.14, CARN 4.83±0.27,
𝑃 ≤ 0.02). In contrast, CARN did not show any effects
on ERKs activation (Figure 5(b)). These results demonstrate
that CARNenhancesmyogenic differentiation acting on IGF-
1/AKT/p70S6 pathway.
3.4. CARN Action during Myoblast Differentiation: Antiox-
idant Action. SOD2 is a critical mitochondrial antioxidant
defense against superoxide produced by respiration [27]. As
shown in Figure 6(a), 5mM CARN increased SOD2 protein
level during early differentiation phase (∙𝑃 ≤ 0.001 Anova
test, in particular 24 h: DM 1.37 ± 0.04, CARN 1.62 ±
0.05, 𝑃 ≤ 0.04). In addition, the multifunctional Ca2+
and calmodulin-dependent protein kinase II (CaMKII) is
recognized to play a crucial role for normal mitochondrial
function and, in particular, in antioxidative metabolism [28].
Immunofluorescence staining results (Figures 6(b) and 6(c))
showed that the CAMKII expression in CARN stimulated
neomyotubes was higher than in control group (24 h–48 h),
suggesting that CARN could ameliorate not only myotubes
formation but also antioxidative mitochondrial pathways.
3.5. CARN Action on Neoformed Myotubes. To study CARN
action on C2C12 myotubes, neoformed myotubes (after 72 h
of differentiation)were stimulatedwith 5mMCARN for 24 h.
Western blot analysis confirmed the evidence observed in
differentiation phase: CARN increased the MyHC protein
content (∙𝑃 ≤ 0.001 Anova test, in particular DM96h 1.12 ±
0.1, CARN 1.40 ± 0.01, 𝑃 ≤ 0.05 versus DM96h), activating
IGF-1/AKT/p70S6 signaling pathway (∙𝑃 ≤ 0.001Anova test,
in particular IGF-1 R: DM96h 1.08 ± 0.03, CARN 1.51 ± 0.09,
𝑃 ≤ 0.01 versus DM96h; pAKT/AKT: DM96h 1.22 ± 0.03,
CARN 1.03 ± 0.03, 𝑃 ≤ 0.001 versus DM96h; pp70S6/p70S6:
DM96h 1.20 ± 0.12, CARN 1.44 ± 0.05, 𝑃 ≤ 0.05 versus
DM96h) and did not influence ERKs pathways (Figure 7).
4. Discussion
In the last decades, numerous studies investigated the positive
CARN supplement action on physical performance shedding
new light on the importance of CARN as a regulator of
skeletal muscle fuel selection and physiological function
(long-chain fatty acids transport), with CARN role not only
as ergogenic aid but also as pharmacological treatment in
pathological conditions characterized by muscle damage [7,
8, 29].
However, to date, no research investigated whether
CARN could positively affect muscle differentiation process.
Our work is the first study to show that increasing skeletal
muscle CARN content in murine immortalized C2C12 cell
line can modulate differentiation process regulating protein
synthesis signaling and oxidative stress response.
The activation of the myogenic regulatory factors Myf5
and MyoD is required to stop satellite cells progression and
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Figure 3: CARN action on C2C12 proliferating myoblasts study. (a), (b) Immunofluorescence analysis of early myogenic transcription
factors Myf5 and MyoD during proliferative phase (24 and 48 h). CARN causes important cells morphological changes in respect to
control: in particular, at 48 h, myoblasts lost their characteristic circular shape (GM) to achieve a new elongated morphology. (c) Phalloidin
Immunofluorescence assay describes the important morphological changes in myoblasts treated with CARN. Scale bar 200𝜇m.
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to turn on myoblast commitment towards early muscle cell
differentiation [20–22]. In our in vitro study, CARNpromotes
the expression of these factors (Figures 2 and 3) implying its
ability to strengthen the satellite cells commitment.
Moreover, CARN enhances the myotubes differentiation
stimulating the expression of the late myogenic regula-
tory factor myogenin and skeletal muscle protein MyHC
(Figure 4), modulating IGF-1/AKT/p70S6 signaling pathway
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(Figures 4 and 5). Moreover, CARN enhances the myotubes
differentiation stimulating the expression of the late myo-
genic regulatory factor myogenin and skeletal muscle protein
MyHC (Figure 4). This and modulating IGF-1/AKT/p70S6
signaling pathway (Figures 4 and 5). The same regula-
tory pathway is still activated by CARN in the neoformed
myotubes (Figure 7). Our data confirm recent in vivo evi-
dence showing that CARN supplementation increases plasma
IGF-1 concentrations and its signaling pathway [30–32].
Moreover, a significant work, which analyzed the CARN
treatment effects on microRNA expression profile in rat
skeletal muscle, suggests that the IGF-1 raise is mediated at
the level of microRNA [33].
Interestingly, several studies have indicated that IGF-1 not
only influences muscle hypertrophy but also inhibits muscle
protein degradation, responsible of skeletal muscle atrophy
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[23, 34, 35]. This effect is induced by AKT signaling pathway
activation, which inhibits the expression of the proteins
(in particular MuRF1 and atrogin-1) involved in ubiquitin-
proteasome system (UPS), a highly regulated mechanism of
intracellular protein degradation [24, 35, 36]. Corroborating
this evidence, several research works, in animal models,
described how CARN supplementation leads to a downreg-
ulation of genes of the ubiquitin proteasome system (UPS),
modulating the release of inhibitors of the UPS such as IGF-1
[37–39].
Our results not only confirm the stimulatory effect of
CARN on IGF-1/AKT/p70S6 pathway but also show that this
effect continues throughout the process of differentiation.
They also show the ability of the CARN to strengthen the
process of myoblasts differentiation. Supported by these
data, we allow recognizing CARN ability to exert beneficial
effects on muscle regeneration, particularly under conditions
associated with an increased activity of the UPS, like in
cancer-related cachexia or sarcopenia state [40, 41].
Sarcopenia, the loss of skeletal muscle mass and function
that occurs with aging, is an accompanying loss in strength,
aerobic capacity, and metabolic rate that contribute to the
reduced function and quality of life [37–41]. The current
first-line therapy for preventing and treating sarcopenia is
resistance exercise [6, 41, 42]. Based on our data, since
CARN promotes muscle commitment, differentiation, and
IGF-1/AKT/p70S6 pathway activation, it might represent an
attractive new drug for the prevention and treatment of
sarcopenia. Furthermore, in our previously published work,
we showed that in a particular category of patients with
lipodystrophy, L-acetyl-carnitine supplementation may be
able to ameliorate the body composition [43]. In addition,
CARN seems to be able not only to modify the body
composition but also to promotemuscle fiber transition, how
demonstrated in rat obese model [44].
In addition, we observed that during differentiation
CARN increased the key proteins involved in antioxidant
process (Figure 6), in line with some in vivo and in vitro stud-
ies on CARN antioxidant and antiradical activities [45, 46].
This antioxidative action of CARN strengthens its position
as a promising candidate for the prevention and treatment of
associated muscle injury conditions. In fact, CARN shows a
dual role in countering the development of muscle wasting:
from a side by opposing the formation of ROS, potent UPS
inducers, and on the other enhancing IGF-1/AKT/p70S6
pathway, potent inhibitor of UPS.
Typically, there is an inverse relationship between efficient
muscle fatty acid 𝛽-oxidation and reactive oxygen species
(ROS) production [46, 47]. Previous studies have concluded
that increased oxidative stress developed in response to lipid
overload causes muscle insulin resistance. In fact, patients
with insulin resistance and/or type 2 diabetes mellitus often
have impaired skeletal muscle oxidative capacity and ineffi-
cient or incomplete fatty acid 𝛽-oxidation [48].
It is important to emphasize that our data allow us to
hypothesize that, in insulin resistance conditions, CARN
supplementation might prevent both incomplete fatty acid
𝛽-oxidation and oxidative stress process, counteracting the
occurrence of muscle insulin resistance conditions.
In summary, considering its importance inmuscle bioen-
ergetics and its antioxidant potential, CARN supplementa-
tion may be considered an aid in condition of CARN defi-
ciency and in skeletal muscle diseases. Despite this potential,
further researches are needed to conclusively elucidate the
mechanisms underlying its protective effects and to verify
their safety and efficacy in treatment of a number of different
muscle diseases.
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